DK1740569T3 - Imidazol-derivater som TAFla-inhibitorer - Google Patents

Imidazol-derivater som TAFla-inhibitorer

Info

Publication number: DK1740569T3
Authority: DK; Denmark
Prior art keywords: taf1α; inhibitors; imidazole derivatives; imidazole; derivatives
Prior art date: 2004-04-22

Application number

DK05731221T

Other languages

Danish (da)

English (en)

Inventor

Christopher Kallus

Holger Heitsch

Andreas Lindenschmidt

Sven Grueneberg

Hauke Szillat

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-22

Filing date

2005-04-07

Publication date

2008-06-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1740569(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-04-07 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2008-06-02 Application granted granted Critical

2008-06-02 Publication of DK1740569T3 publication Critical patent/DK1740569T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK05731221T 2004-04-22 2005-04-07 Imidazol-derivater som TAFla-inhibitorer DK1740569T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102004020186A DE102004020186A1 (de)	2004-04-22	2004-04-22	Heterocyclylessigsäuren als Inhibitoren von TAFla
PCT/EP2005/003630 WO2005105781A1 (fr)	2004-04-22	2005-04-07	Derives d'imidazole servant d'inhibiteurs de tafia

Publications (1)

Publication Number	Publication Date
DK1740569T3 true DK1740569T3 (da)	2008-06-02

Family

ID=34964308

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05731221T DK1740569T3 (da)	2004-04-22	2005-04-07	Imidazol-derivater som TAFla-inhibitorer

Country Status (34)

Country	Link
EP (2)	EP1740569B1 (fr)
JP (1)	JP4939401B2 (fr)
KR (1)	KR101162047B1 (fr)
CN (1)	CN100572376C (fr)
AR (1)	AR053302A1 (fr)
AT (2)	ATE386737T1 (fr)
AU (1)	AU2005238144B2 (fr)
BR (1)	BRPI0510159A (fr)
CA (1)	CA2563401C (fr)
CR (1)	CR8650A (fr)
CY (1)	CY1108087T1 (fr)
DE (2)	DE102004020186A1 (fr)
DK (1)	DK1740569T3 (fr)
EC (1)	ECSP066941A (fr)
ES (1)	ES2299026T3 (fr)
HR (1)	HRP20080099T3 (fr)
IL (1)	IL178672A (fr)
MA (1)	MA28543B1 (fr)
MY (1)	MY140903A (fr)
NI (1)	NI200600217A (fr)
NO (1)	NO20065320L (fr)
NZ (1)	NZ550757A (fr)
PE (1)	PE20060172A1 (fr)
PL (1)	PL1740569T3 (fr)
PT (1)	PT1740569E (fr)
RS (1)	RS50553B (fr)
RU (1)	RU2375356C2 (fr)
SI (1)	SI1740569T1 (fr)
TN (1)	TNSN06341A1 (fr)
TW (1)	TWI359016B (fr)
UA (1)	UA87306C2 (fr)
UY (1)	UY28868A1 (fr)
WO (1)	WO2005105781A1 (fr)
ZA (1)	ZA200607668B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20150514T1 (hr)	2006-12-06	2015-09-11	Sanofi	DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
MX2009008777A (es) *	2007-02-13	2009-08-25	Schering Corp	Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
EP2185544B1 (fr)	2007-07-19	2014-11-26	Cymabay Therapeutics, Inc.	Derives subtitues heterocycliques a liaison n de pyrrole, pyrazole, imidazole, triazole et tetrazole comme agonistes de recepteurs rup3 ou gpr119 utilises dans le traitement du diabete et des troubles metaboliques
WO2009103432A2 (fr) *	2008-02-21	2009-08-27	Sanofi-Aventis	Sondes d’imagerie à liaison covalente
RU2502736C2 (ru) *	2008-06-06	2013-12-27	Санофи-Авентис	МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa
CA2741783A1 (fr)	2008-10-29	2010-05-06	Taisho Pharmaceutical Co., Ltd.	Compose ayant une activite inhibitrice des tafia
ES2431068T3 (es)	2009-05-15	2013-11-25	Sanofi	Proceso para la preparación de un compuesto útil como un inhibidor de TAFIa
FR2947266B1 (fr) *	2009-06-26	2011-06-17	Servier Lab	Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2483281B1 (fr)	2009-10-01	2014-06-04	Cymabay Therapeutics, Inc.	Sels de la tétrazol-1-yl-phénoxyméthyl-thiazol-2-yl-pipéridinyl-pyrimidine substituée
KR101704095B1 (ko)	2010-03-18	2017-02-09	다이이찌 산쿄 가부시키가이샤	시클로알킬기로 치환된 이미다졸 유도체
US8946443B2 (en)	2010-03-18	2015-02-03	Daiichi Sankyo Company, Limited	Cyclopropanecarboxylic acid derivative
CA2814911A1 (fr)	2010-11-11	2012-05-18	Sanofi	Procede de fabrication de derives d'acide 3-(6-amino-pyridin-3yl)-2-acrylique
US9145385B2 (en)	2011-11-25	2015-09-29	Sanofi	Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
US9102657B2 (en) *	2011-11-25	2015-08-11	Sanofi	Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
EP2782574B1 (fr)	2011-11-25	2016-03-30	Sanofi	Sel du (r) ethyl-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)-propanoate
EP2805705B1 (fr)	2013-05-23	2016-11-09	IP Gesellschaft für Management mbH	Emballage comprenant des unités d'administration des sels de sodium de l'acide (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionique
CN105263928A (zh)	2013-06-10	2016-01-20	赛诺菲	作为TAFIa的抑制剂的大环脲衍生物、其制备及其作为药物的用途
EP3437641A4 (fr)	2016-03-29	2019-11-20	Daiichi Sankyo Company, Limited	Agent thérapeutique contre les maladies inflammatoires de l'intestin
WO2018026890A1 (fr)	2016-08-03	2018-02-08	Cymabay Therapeutics	Composés d'aryle d'oxyméthylène pour le traitement de maladies gastro-intestinales inflammatoires ou de troubles gastro-intestinaux

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2356838A1 (fr) *	1998-12-24	2000-07-06	Fujisawa Pharmaceutical Co., Ltd.	Composes d'imidazole et utilisation medicinale de ces composes
WO2003013526A1 (fr)	2001-08-08	2003-02-20	Merck & Co. Inc.	Composes anticoagulants
WO2003061653A1 (fr)	2002-01-22	2003-07-31	Pfizer Limited	Acides 3-(imidazolyl)-2-aminopropanoiques servant d'inhibiteurs tafia pour traiter des maladies thrombotiques

2004
- 2004-04-22 DE DE102004020186A patent/DE102004020186A1/de not_active Withdrawn
2005
- 2005-04-06 PE PE2005000382A patent/PE20060172A1/es not_active Application Discontinuation
- 2005-04-07 DK DK05731221T patent/DK1740569T3/da active
- 2005-04-07 BR BRPI0510159-0A patent/BRPI0510159A/pt not_active Application Discontinuation
- 2005-04-07 ES ES05731221T patent/ES2299026T3/es not_active Expired - Lifetime
- 2005-04-07 AU AU2005238144A patent/AU2005238144B2/en not_active Ceased
- 2005-04-07 AT AT05731221T patent/ATE386737T1/de active
- 2005-04-07 PL PL05731221T patent/PL1740569T3/pl unknown
- 2005-04-07 PT PT05731221T patent/PT1740569E/pt unknown
- 2005-04-07 EP EP05731221A patent/EP1740569B1/fr not_active Expired - Lifetime
- 2005-04-07 RU RU2006141246/04A patent/RU2375356C2/ru not_active IP Right Cessation
- 2005-04-07 NZ NZ550757A patent/NZ550757A/en not_active IP Right Cessation
- 2005-04-07 DE DE502005002927T patent/DE502005002927D1/de not_active Expired - Lifetime
- 2005-04-07 CA CA2563401A patent/CA2563401C/fr not_active Expired - Fee Related
- 2005-04-07 SI SI200530185T patent/SI1740569T1/sl unknown
- 2005-04-07 CN CNB2005800115593A patent/CN100572376C/zh not_active Expired - Fee Related
- 2005-04-07 RS RSP-2008/0107A patent/RS50553B/sr unknown
- 2005-04-07 WO PCT/EP2005/003630 patent/WO2005105781A1/fr not_active Ceased
- 2005-04-07 JP JP2007508756A patent/JP4939401B2/ja not_active Expired - Fee Related
- 2005-04-07 EP EP07017340A patent/EP1864979B1/fr not_active Expired - Lifetime
- 2005-04-07 AT AT07017340T patent/ATE523505T1/de active
- 2005-04-07 HR HR20080099T patent/HRP20080099T3/xx unknown
- 2005-04-07 KR KR1020067021881A patent/KR101162047B1/ko not_active Expired - Fee Related
- 2005-04-20 MY MYPI20051748A patent/MY140903A/en unknown
- 2005-04-20 AR ARP050101556A patent/AR053302A1/es not_active Application Discontinuation
- 2005-04-20 TW TW094112493A patent/TWI359016B/zh not_active IP Right Cessation
- 2005-04-22 UY UY28868A patent/UY28868A1/es unknown
- 2005-07-04 UA UAA200612254A patent/UA87306C2/ru unknown
2006
- 2006-09-13 ZA ZA200607668A patent/ZA200607668B/en unknown
- 2006-09-20 NI NI200600217A patent/NI200600217A/es unknown
- 2006-09-22 CR CR8650A patent/CR8650A/es unknown
- 2006-10-17 IL IL178672A patent/IL178672A/en not_active IP Right Cessation
- 2006-10-19 MA MA29399A patent/MA28543B1/fr unknown
- 2006-10-20 EC EC2006006941A patent/ECSP066941A/es unknown
- 2006-10-20 TN TNP2006000341A patent/TNSN06341A1/en unknown
- 2006-11-20 NO NO20065320A patent/NO20065320L/no not_active Application Discontinuation
2008
- 2008-05-12 CY CY20081100491T patent/CY1108087T1/el unknown

Also Published As

Publication number	Publication date
ES2299026T3 (es)	2008-05-16
AU2005238144A1 (en)	2005-11-10
JP2007533672A (ja)	2007-11-22
IL178672A (en)	2011-08-31
HRP20080099T3 (en)	2008-03-31
WO2005105781A1 (fr)	2005-11-10
DE502005002927D1 (de)	2008-04-03
NI200600217A (es)	2008-06-17
MY140903A (en)	2010-01-29
CA2563401A1 (fr)	2005-11-10
NO20065320L (no)	2007-01-12
EP1740569A1 (fr)	2007-01-10
TNSN06341A1 (en)	2008-02-22
PL1740569T3 (pl)	2008-07-31
ATE523505T1 (de)	2011-09-15
IL178672A0 (en)	2007-02-11
DE102004020186A1 (de)	2005-11-17
CA2563401C (fr)	2012-08-07
HK1101823A1 (zh)	2007-10-26
NZ550757A (en)	2010-06-25
CY1108087T1 (el)	2014-02-12
EP1740569B1 (fr)	2008-02-20
CR8650A (es)	2007-12-04
CN1950357A (zh)	2007-04-18
TWI359016B (en)	2012-03-01
KR101162047B1 (ko)	2012-07-04
EP1864979A1 (fr)	2007-12-12
EP1864979B1 (fr)	2011-09-07
TW200602325A (en)	2006-01-16
AU2005238144B2 (en)	2010-08-26
RU2375356C2 (ru)	2009-12-10
UY28868A1 (es)	2005-11-30
AR053302A1 (es)	2007-05-02
UA87306C2 (en)	2009-07-10
SI1740569T1 (sl)	2008-06-30
BRPI0510159A (pt)	2007-10-02
ECSP066941A (es)	2006-12-20
KR20070007346A (ko)	2007-01-15
CN100572376C (zh)	2009-12-23
ZA200607668B (en)	2008-03-26
MA28543B1 (fr)	2007-04-03
JP4939401B2 (ja)	2012-05-23
PT1740569E (pt)	2008-03-31
ATE386737T1 (de)	2008-03-15
RU2006141246A (ru)	2008-06-10
RS50553B (sr)	2010-05-07
PE20060172A1 (es)	2006-03-31

Publication	Publication Date	Title
DK1789041T3 (da)	2008-09-08	Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1797042T3 (da)	2009-03-02	Indozolonderivater som 11B-HSD1-inhibitorer
DK1926722T3 (da)	2011-12-19	Substituerede benzimidazoler som kinaseinhibitorer
DK1586319T3 (da)	2010-02-08	Thiadiazolidinoner som GSK-3-inhibitorer
DK1585749T3 (da)	2008-09-22	Diazepinoindol-derivater som kinaseinhibitorer
DK2094263T3 (da)	2013-12-02	2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
ATE520671T1 (de)	2011-09-15	Pyrimidin-harnstoff-derivate als kinase-hemmer
DK1959951T3 (da)	2010-03-01	Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer
DK1663232T3 (da)	2008-02-04	Benzimidazolderivater som human chymase-inhibitorer
ATE452631T1 (de)	2010-01-15	N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
DK2086939T3 (da)	2010-10-11	Pyridiacarboxamid som II-beta-HSDI-inhibitorer
PT1586571E (pt)	2008-09-08	Inibidores da dipeptidil-peptidase
DK2078001T3 (da)	2010-07-19	Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer
DK2220070T3 (da)	2011-07-04	2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DK1725553T3 (da)	2008-08-18	Tetrahydropyridoindolderivater
DK1828167T3 (da)	2014-10-20	Acrylamidderivater som antibiotiske midler
DK1846394T3 (da)	2012-01-16	Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
ATE540935T1 (de)	2012-01-15	Chinazolinderivate
DK1740569T3 (da)	2008-06-02	Imidazol-derivater som TAFla-inhibitorer
ATE383361T1 (de)	2008-01-15	Pyrrazolopyrimidinderivate
ATE417830T1 (de)	2009-01-15	Sulfonylbenzimidazolderivate
DK1763517T3 (da)	2011-06-06	Pyrimidinderivater som 11beta-HSD1-inhibitorer
DK2049480T3 (da)	2014-01-20	2-arylindolderivater som mPGES-1-hæmmere
ZA200705068B (en)	2008-10-29	Hydantoin derivatives useful as metalloproteinase inhibitors
DK1711177T3 (da)	2008-09-29	1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer